DCPH
Price:
$25.59
Market Cap:
$2.21B
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2017-09-28
Stock Exchange
NASDAQ
Ticker
DCPH
According to Deciphera Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -56.29%. This represents a change of 327.18% compared to the average of -13.18% of the last 4 quarters.
The mean historical ROE of Deciphera Pharmaceuticals, Inc. over the last ten years is -35.18%. The current -56.29% ROE has changed 60.00% with respect to the historical average. Over the past ten years (40 quarters), DCPH's ROE was at its highest in in the September 2017 quarter at 7.16%. The ROE was at its lowest in in the December 2021 quarter at -29.01%.
Average
-35.18%
Median
-35.66%
Minimum
-97.41%
Maximum
18.56%
Discovering the peaks and valleys of Deciphera Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 98.74%
Maximum Annual ROE = 18.56%
Minimum Annual Increase = -247.26%
Minimum Annual ROE = -97.41%
| Year | ROE | Change |
|---|---|---|
| 2023 | -55.55% | 6.08% |
| 2022 | -52.37% | -46.24% |
| 2021 | -97.41% | 98.74% |
| 2020 | -49.02% | 39.88% |
| 2019 | -35.04% | -1.75% |
| 2018 | -35.66% | 30.49% |
| 2017 | -27.33% | -247.26% |
| 2016 | 18.56% | 8.00% |
The current ROE of Deciphera Pharmaceuticals, Inc. (DCPH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-68.44%
5-year avg
-57.88%
10-year avg
-35.18%
Deciphera Pharmaceuticals, Inc.’s ROE is greater than Calliditas Therapeutics AB (publ) (-84.68%), less than DICE Therapeutics, Inc. (56.07%), greater than Embecta Corp. (-13.41%), less than Provention Bio, Inc. (133.43%), greater than Longboard Pharmaceuticals, Inc. (-16.26%), greater than Fusion Pharmaceuticals Inc. (-49.34%), less than Taro Pharmaceutical Industries Ltd. (3.06%), less than Myovant Sciences Ltd. (49.79%), greater than Chinook Therapeutics, Inc. (-41.23%), less than NuVasive, Inc. (4.86%),
| Company | ROE | Market cap |
|---|---|---|
| -84.68% | $2.15B | |
| 56.07% | $2.27B | |
| -13.41% | $646.54M | |
| 133.43% | $2.38B | |
| -16.26% | $2.34B | |
| -49.34% | $1.83B | |
| 3.06% | $1.62B | |
| 49.79% | $2.62B | |
| -41.23% | $2.71B | |
| 4.86% | $2.08B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Deciphera Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Deciphera Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Deciphera Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Deciphera Pharmaceuticals, Inc. (DCPH)?
What is the highest ROE for Deciphera Pharmaceuticals, Inc. (DCPH)?
What is the 3-year average ROE for Deciphera Pharmaceuticals, Inc. (DCPH)?
What is the 5-year average ROE for Deciphera Pharmaceuticals, Inc. (DCPH)?
How does the current ROE for Deciphera Pharmaceuticals, Inc. (DCPH) compare to its historical average?